Citadel Advisors’s NanoViricides NNVC Stock Holding History

Citadel Advisors’s Portfolio NNVC Stock Details NNVC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-100	Closed	-$117	–	14226
2025 Q1	$117	Sell	100 -400	-80%	-$508	﹤0.01%	14329
2024 Q4	$715	Sell	500 -12,500	-96%	-$18K	﹤0.01%	14283
2024 Q3	$19.5K	Buy	+13,000	New	+$24.1K	﹤0.01%	12793
2024 Q1	–	Sell	-1,000	Closed	-$1.02K	–	15204
2023 Q4	$1.02K	Buy	1,000 +500	+100%	+$578	﹤0.01%	13895
2023 Q3	$670	Buy	+500	New	+$707	﹤0.01%	14006
2023 Q2	–	Sell	-2,600	Closed	-$3.05K	–	14952
2023 Q1	$3.05K	Sell	2,600 -43,700	-94%	-$59K	﹤0.01%	14078
2022 Q4	$51.4K	Sell	46,300 -400	-0.9%	-$624	﹤0.01%	12101
2022 Q3	$81K	Buy	+46,700	New	+$102K	﹤0.01%	11275
2021 Q4	–	Sell	-13,700	Closed	-$64K	–	14436
2021 Q3	$64K	Buy	+13,700	New	+$57.1K	﹤0.01%	13221
2015 Q4	–	Sell	-315	Closed	-$7K	–	9024
2015 Q3	$7K	Buy	+315	New	+$8.34K	﹤0.01%	8570
2014 Q3	–	Sell	-360	Closed	-$30K	–	8307
2014 Q2	$30K	Buy	+360	New	+$25.6K	﹤0.01%	7078

Other funds holding NNVC

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

MFS

Miller Financial Services Marshall, Michigan $124M AUM 17.62% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citadel Advisors's NNVC Position: Q1 2026 in Review

Citadel Advisors sold out of NanoViricides (NNVC) in Q1 2026, closing a stake of 79,915 shares — an estimated $83.6K sold.

Citadel Advisors first reported a position in NNVC in Q1 2014 and held it in 22 quarters. The position peaked at $143K in Q1 2021. 48 funds tracked by Wall St. Rank hold NNVC as of Q1 2026.

Citadel Advisors reported no remaining NanoViricides position as of Q1 2026 after selling out during the quarter.
Citadel Advisors sold 79,915 NanoViricides shares in Q1 2026, an estimated $83.6K.
Citadel Advisors first reported a position in NanoViricides in Q1 2014 and held it in 22 quarters.
Citadel Advisors's NanoViricides position peaked at $143K in Q1 2021.
48 funds tracked by Wall St. Rank held NanoViricides as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.